Viokase 16, Viokase16 Plus Nexium and Nexium Alone

Overview

Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic abdominal pain in patients with small duct chronic pancreatitis in a superior fashion compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an increase in quality of life. Our objective is to elucidate the role of Nexium in the control of pancreatic pain, quality of life, and narcotic usage alone or when added to Viokase 16. Our endpoints are the reduction of abdominal pain, decreased pain medication usage, decreased ER visits and decreased hospital admissions for abdominal pain.

Full Title of Study: “A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2011

Interventions

  • Drug: Nexium (esomeprazole magnesium)
    • one 40 mg capsule per day for one month
  • Drug: Placebo to Nexium
    • one capsule per day for one month
  • Drug: Viokase 16 (pancrelipase) + Nexium
    • Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
  • Drug: Viokase 16 + placebo to Nexium
    • Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month

Arms, Groups and Cohorts

  • Active Comparator: Nexium alone
    • Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
  • Placebo Comparator: Placebo to Nexium, alone
    • Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
  • Active Comparator: Viokase 16 (pancrelipase) + Nexium
    • Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
  • Placebo Comparator: Viokase 16 + placebo to Nexium
    • Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone

Clinical Trial Outcome Measures

Primary Measures

  • Reduction of Abdominal Pain for Participants Taking Nexium Alone.
    • Time Frame: 4 months
    • To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
  • Reduction of Abdominal Pain for Participants Taking Placebo to Nexium
    • Time Frame: 4 months
    • To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
  • Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Nexium
    • Time Frame: 4 months
    • To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain
  • Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Placebo.
    • Time Frame: 4 months
    • To elucidate the role of Viokase 16 and Nexium in the control of pancreatic pain

Participating in This Clinical Trial

Inclusion Criteria

1. Males and females age 18 to 75 years inclusive. Female subjects of child bearing potential or less than two years post-menopausal must use a medically acceptable form of birth control or barrier method and have a negative pregnancy test prior to entry into study. 2. History of abdominal pain associated with chronic pancreatitis 3. Evidence of chronic pancreatitis as manifested by an abnormal secretin test, calcification of the pancreas on plain film, an abnormal CT showing a dilated pancreatic duct and/or atrophy, an abnormal Endoscopicretrogradecholangeopancreatography (ERCP), or diffuse changes on Endoscopic Ultrasound (EUS), fecal elastase > 100ug/g stool, or serum trypsinogen > 20ng/ml - Exclusion Criteria:

1. Subjects on enzyme therapy within the last 14 days, proton pump inhibitor (PPI)within the last 7 days, or octreotide within 48 hours. 2. Subjects with known hypersensitivity to pork or exogenous or pancreatic enzymes. 3. Female subjects who are pregnant or lactating 4. Subject use of enzyme therapy other than that called for in this study 5. Subject use of therapeutic amounts of antacids or H2 receptor antagonists during the course of the study. 6. Past history of documented steatorrhea by 72 hour fecal fat determination or current history consistent with steatorrhea -

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Florida
  • Collaborator
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Phillip P Toskes, M.D., Principal Investigator, University of Florida

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.